Cuba vs Myanmar: Access to anti-retroviral drugs, female
Cuba
78.0%
in 2024
Myanmar
78.0%
in 2024
Cuba rank
60th
Myanmar rank
60th
Access to anti-retroviral drugs, female over time
- Cuba
- Myanmar
How they compare
Cuba currently reports 78.0% against 78.0% in Myanmar, a difference of 0.0%.
The two have swapped places 3 times across 25 shared years of data; in 2000 it was Cuba ahead.
Cuba ranks 60th and Myanmar ranks 60th of 141 countries.
Cuba has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Cuba | Myanmar | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 14.0% | 2.5% | 11.5% | Cuba |
| 2010s | 50.9% | 39.2% | 11.7% | Cuba |
| 2020s | 76.2% | 75.6% | 0.6% | Cuba |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Cuba or Myanmar?
- Cuba, at 78.0% against 78.0% in Myanmar as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Cuba and Myanmar?
- 0.0%, with Cuba ahead.
- How many years of comparable data are there for Cuba and Myanmar?
- 25 years are reported by both, from 2000 to 2024.
- How do Cuba and Myanmar rank globally for access to anti-retroviral drugs, female?
- Cuba ranks 60th and Myanmar ranks 60th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.